|Mr. Kevin T. Conroy||Chairman of The Board & CEO||2.37M||2.44M||1966|
|Mr. Jeffrey T. Elliott CFA||Exec. VP, CFO & COO||904.67k||N/A||1978|
|Mr. D. Scott Coward||Chief Legal Officer||847.28k||2.59M||1965|
|Mr. Graham P. Lidgard||Emeritus Chief Science Officer||937.04k||5M||1949|
|Mr. Everett V. Cunningham||Chief Commercial Officer||1.01M||N/A||1966|
|Dr. Jorge A. Garces Ph.D.||Chief Science Officer||N/A||N/A||1972|
|Mr. Sri Kalluri||Chief Information Officer||N/A||N/A||N/A|
|Ms. Megan Jones||Associate Mang. of Investor Relations||N/A||N/A||N/A|
|Mr. Tim Caprez||Chief Compliance Counsel & VP||N/A||N/A||N/A|
|Mr. Vic Parker||Head of Sales||N/A||N/A||N/A|
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Exact Sciences Corporation’s ISS Governance QualityScore as of September 1, 2022 is 4. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 4; Compensation: 5.